Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Keitaro Yamanaka, Keiichi Washio, Akiko Uchida, Yuki Sasagawa, Masashi Nishimoto, Yui Yamasaki, Satoshi Nagamata, Yoshito Terai
Formaat: Artikel
Taal:English
Gepubliceerd in: Taylor & Francis Group 2023-12-01
Reeks:Gynecological Endocrinology
Onderwerpen:
Adenomyosis
relugolix
fibroids
GnRH antagonist
GnRH agonist
Online toegang:https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121

Internet

https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121

Gelijkaardige items